High-Dose Nevirapine: Safety, Pharmacokinetics, And Antiviral Effect In Patients With Human Immunodeficiency Virus Infection

Authors:
  • SCSarah H. Cheeseman
    Sarah H. Cheeseman
  • MMMargaret Mclaughlin
    Margaret Mclaughlin
  • RMRobert Murphy
    Robert Murphy
  • SSStephen A. Spector
    Stephen A. Spector
  • TGThomas C. Greenough
    Thomas C. Greenough
  • JSJohn L. Sullivan
    John L. Sullivan
  • DHDavid Hall
    David Hall
  • MMMaureen Myers
    Maureen Myers
  • MLMichael Lamson
    Michael Lamson
  • DRDouglas D. Richman
    Douglas D. Richman

Abstract
Nevirapine, a potent nonnucleoside reverse transcriptase inhibitor, produces a transient antiviral effect at ⩽200 mg/day due to the selection of resistant virus. To examine if higher levels of nevirapine could produce sustained antiviral activity, its safety, pharmacokinetics, and antiviral activity at 400 mg/day were studied in 21 patients. There was a rapid reduction in immune complex-dissociated p24 antigen and serum human immunodeficiency virus RNA concentration in all patients, and 8 of 10 patients had > 50% reduction at 8 weeks. Nevirapine-resistant virus was isolated from all subjects tested at 12 weeks: The mean plasma trough level (4.0 µg/mL [l5.8µg/M]) exceeded the mean IC50 of resistant virus. Rash developed in 48% of patients and was a dose-limiting toxicity factor in 6. These data suggest that clinical testing of potent antiviral compounds that select for drug-resistant virus is justified to determine if serum levels of drug sufficient to overcome resistant virus can be attained.